Trial Profile
Comparision of safety profile of sorafenib between hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) patients: A real life experience in Japanese patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer; Renal cell carcinoma
- Focus Adverse reactions
- 17 Nov 2015 New trial record